tiprankstipranks
Trending News
More News >
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
US Market
Advertisement

Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

Compare
428 Followers
See the Price Targets and Ratings of:

TERN Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Terns
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TERN Stock 12 Month Forecast

Average Price Target

$13.69
▲(88.05% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $13.69 with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 88.05% change from the last price of $7.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,8.516923076923076,9.473846153846154,10.430769230769231,11.387692307692308,12.344615384615384,13.301538461538462,14.258461538461539,15.215384615384615,16.172307692307694,17.12923076923077,18.086153846153845,19.043076923076924,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,8.031538461538462,8.503076923076923,8.974615384615385,9.446153846153846,9.917692307692308,10.38923076923077,10.86076923076923,11.332307692307692,11.803846153846154,12.275384615384615,12.746923076923077,13.218461538461538,{"y":13.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,7.516923076923076,7.473846153846154,7.43076923076923,7.387692307692308,7.344615384615384,7.3015384615384615,7.258461538461538,7.2153846153846155,7.172307692307692,7.1292307692307695,7.086153846153846,7.043076923076923,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$13.69Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TERN
H.C. Wainwright
H.C. Wainwright
$7.44
Hold
2.20%
Upside
Initiated
09/04/25
Terns Pharmaceuticals assumed with a Neutral at H.C. WainwrightTerns Pharmaceuticals assumed with a Neutral at H.C. Wainwright
Oppenheimer Analyst forecast on TERN
Oppenheimer
Oppenheimer
$20
Buy
174.73%
Upside
Reiterated
09/04/25
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), Ascentage Pharma Group International Unsponsored ADR (AAPG)
William Blair Analyst forecast on TERN
William Blair
William Blair
$5.5$7
Hold
-3.85%
Downside
Reiterated
09/04/25
William Blair Keeps Their Hold Rating on Terns Pharmaceuticals (TERN)
Mizuho Securities Analyst forecast on TERN
Mizuho Securities
Mizuho Securities
$14
Buy
92.31%
Upside
Reiterated
09/04/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Terns Pharmaceuticals (NASDAQ: TERN) and Novan (NASDAQ: NOVN)we reiterate our OP rating on TERN
TD Cowen Analyst forecast on TERN
TD Cowen
TD Cowen
Buy
Reiterated
08/05/25
1:30 AM TERNS PHARMACEUTICALS (NASDAQ: TERN) Buy (1) ESG Target: NA 2Q25: PH1 CML '701 DOSE EXPANSION & PH2 '601 OBESITY DATA BOTH DUE IN 4Q25 THE TD COWEN INSIGHT The '701 Ph1 CARDINAL Part 2 dose expansion in CML is enrolling. Data from a larger pt cohort w/ longer tx duration and readthrough to the 6-mo MMR approval endpoint is due 4Q25, along with add'l Part 1 data. The '601 Ph2 FALCON dose-finding obesity trial is enrolling with data due early 4Q25. The 1º EP is % change from BL in body weight vs PBO at 12wks. Cash of $315M gives runway to 2028E.
Citizens JMP Analyst forecast on TERN
Citizens JMP
Citizens JMP
$20
Buy
174.73%
Upside
Reiterated
06/17/25
Citizens JMP Keeps Their Buy Rating on Terns Pharmaceuticals (TERN)
BMO Capital Analyst forecast on TERN
BMO Capital
BMO Capital
$15
Buy
106.04%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN), Merus (NASDAQ: MRUS) and Terns Pharmaceuticals (NASDAQ: TERN)
J.P. Morgan Analyst forecast on TERN
J.P. Morgan
J.P. Morgan
$14
Hold
92.31%
Upside
Reiterated
05/09/25
J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)
Westpark Capital Analyst forecast on TERN
Westpark Capital
Westpark Capital
$7.5
Hold
3.02%
Upside
Reiterated
12/04/24
Hold Rating on Terns Pharmaceuticals' TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on TERN
H.C. Wainwright
H.C. Wainwright
$7.44
Hold
2.20%
Upside
Initiated
09/04/25
Terns Pharmaceuticals assumed with a Neutral at H.C. WainwrightTerns Pharmaceuticals assumed with a Neutral at H.C. Wainwright
Oppenheimer Analyst forecast on TERN
Oppenheimer
Oppenheimer
$20
Buy
174.73%
Upside
Reiterated
09/04/25
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), Ascentage Pharma Group International Unsponsored ADR (AAPG)
William Blair Analyst forecast on TERN
William Blair
William Blair
$5.5$7
Hold
-3.85%
Downside
Reiterated
09/04/25
William Blair Keeps Their Hold Rating on Terns Pharmaceuticals (TERN)
Mizuho Securities Analyst forecast on TERN
Mizuho Securities
Mizuho Securities
$14
Buy
92.31%
Upside
Reiterated
09/04/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Terns Pharmaceuticals (NASDAQ: TERN) and Novan (NASDAQ: NOVN)we reiterate our OP rating on TERN
TD Cowen Analyst forecast on TERN
TD Cowen
TD Cowen
Buy
Reiterated
08/05/25
1:30 AM TERNS PHARMACEUTICALS (NASDAQ: TERN) Buy (1) ESG Target: NA 2Q25: PH1 CML '701 DOSE EXPANSION & PH2 '601 OBESITY DATA BOTH DUE IN 4Q25 THE TD COWEN INSIGHT The '701 Ph1 CARDINAL Part 2 dose expansion in CML is enrolling. Data from a larger pt cohort w/ longer tx duration and readthrough to the 6-mo MMR approval endpoint is due 4Q25, along with add'l Part 1 data. The '601 Ph2 FALCON dose-finding obesity trial is enrolling with data due early 4Q25. The 1º EP is % change from BL in body weight vs PBO at 12wks. Cash of $315M gives runway to 2028E.
Citizens JMP Analyst forecast on TERN
Citizens JMP
Citizens JMP
$20
Buy
174.73%
Upside
Reiterated
06/17/25
Citizens JMP Keeps Their Buy Rating on Terns Pharmaceuticals (TERN)
BMO Capital Analyst forecast on TERN
BMO Capital
BMO Capital
$15
Buy
106.04%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN), Merus (NASDAQ: MRUS) and Terns Pharmaceuticals (NASDAQ: TERN)
J.P. Morgan Analyst forecast on TERN
J.P. Morgan
J.P. Morgan
$14
Hold
92.31%
Upside
Reiterated
05/09/25
J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)
Westpark Capital Analyst forecast on TERN
Westpark Capital
Westpark Capital
$7.5
Hold
3.02%
Upside
Reiterated
12/04/24
Hold Rating on Terns Pharmaceuticals' TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Terns Pharmaceuticals

1 Month
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+6.75%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +6.75% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+12.79%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +12.79% per trade.
1 Year
Silvan TuerkcanCitizens JMP
Success Rate
11/20 ratings generated profit
55%
Average Return
+13.71%
reiterated a buy rating 3 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +13.71% per trade.
2 Years
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+37.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +37.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TERN Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
7
6
5
5
6
Buy
1
0
0
1
1
Hold
5
3
2
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
9
7
7
10
In the current month, TERN has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TERN average Analyst price target in the past 3 months is 13.69.
Each month's total comprises the sum of three months' worth of ratings.

TERN Financial Forecast

TERN Earnings Forecast

Next quarter’s earnings estimate for TERN is -$0.30 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.26. TERN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.42% of the time in the same period. In the last calendar year TERN has Outperformed its overall industry.
Next quarter’s earnings estimate for TERN is -$0.30 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.26. TERN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.42% of the time in the same period. In the last calendar year TERN has Outperformed its overall industry.
No data currently available

TERN Sales Forecast

Next quarter’s sales forecast for TERN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TERN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year TERN has Preformed in-line its overall industry.
Next quarter’s sales forecast for TERN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TERN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year TERN has Preformed in-line its overall industry.

TERN Stock Forecast FAQ

What is TERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Terns Pharmaceuticals’s 12-month average price target is 13.69.
    What is TERN’s upside potential, based on the analysts’ average price target?
    Terns Pharmaceuticals has 88.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TERN a Buy, Sell or Hold?
          Terns Pharmaceuticals has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Terns Pharmaceuticals’s price target?
            The average price target for Terns Pharmaceuticals is 13.69. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $7.00. The average price target represents 88.05% Increase from the current price of $7.28.
              What do analysts say about Terns Pharmaceuticals?
              Terns Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of TERN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis